€1 aan- en verkoopkosten, 2% rente op uw saldo, gratis periodiek beleggen, rekening beschermd tot €100K + gratis aandeel t.w.v. €50
✅ Geen reclames maar wel meer functies op het snelst groeiende beursforum van de Benelux? ✅
Registreer binnen 1 minuut
ARGENX SE - ARGX - NL0010832176
-
- Regelmatige poster
- Berichten: 177
- Lid geworden op: 27 dec 2021 11:12
- Heeft bedankt: 33 maal
- Is bedankt: 74 maal
Re: ARGENX SE - ARGX - NL0010832176
Mid januari gekocht en het was niet de bodem maar nog vol vertrouwen. Nog bijna 3% tot ik uit het rood ben.
Financiële kalender voor 2022, zijn er nog meer data zoals verwachtingen van fase onderzoeken die wij dit jaar mogen verwachten?
Financial Calendar
March 3, 2022
Full Year and Fourth Quarter 2021 Financial Results
May 10, 2022
Annual General Meeting
May 12, 2022
First Quarter 2022 Financial Results
July 28, 2022
Half Year and Second Quarter 2022 Financial Results
Oct 27, 2022
Third Quarter 2022
Financiële kalender voor 2022, zijn er nog meer data zoals verwachtingen van fase onderzoeken die wij dit jaar mogen verwachten?
Financial Calendar
March 3, 2022
Full Year and Fourth Quarter 2021 Financial Results
May 10, 2022
Annual General Meeting
May 12, 2022
First Quarter 2022 Financial Results
July 28, 2022
Half Year and Second Quarter 2022 Financial Results
Oct 27, 2022
Third Quarter 2022
Ageas - Argen-X - Besi - Disney - IWDA - Galapagos - KBC - Shell - Sofina - UCB
- Multani
- Ervaren poster
- Berichten: 919
- Lid geworden op: 24 nov 2021 21:58
- Heeft bedankt: 123 maal
- Is bedankt: 395 maal
Re: ARGENX SE - ARGX - NL0010832176
Die kans is groot en dan geven beurshuizen vaak aan dat een koersdoel een verwachting is binnen 12 maanden. De meesten geven elke twee maanden wel een ander advies.Bel-Investor schreef: ↑01 feb 2022 19:02$279,38 nu op de Nasdaq, over een paar weken gaat de analist zeker het koersdoel weer verhogen?![]()
Voorlopige opening staat op €240 maar met het slot in Amerika en positieve futures denk ik dat wij vandaag naar €250 gaan.
- Karl
- Forumveteraan
- Berichten: 1995
- Lid geworden op: 23 nov 2021 08:53
- Heeft bedankt: 292 maal
- Is bedankt: 638 maal
Re: ARGENX SE - ARGX - NL0010832176
Knap gevonden Multani nu komt het advies ook door via andere wegen:
Morgan Stanley herhaalt het houdadvies voor arGEN-X
woensdag 2 februari 2022 - 07:03u -
Morgan Stanley verlaagt het koersdoel van arGEN-X naar € 243,00 van € 299,00. Het houdadvies van woensdag 19 januari 2022 wordt herhaald. Dit vorige advies heeft geresulteerd in een rendement van -4,42%.
Morgan Stanley herhaalt het houdadvies voor arGEN-X
woensdag 2 februari 2022 - 07:03u -
Morgan Stanley verlaagt het koersdoel van arGEN-X naar € 243,00 van € 299,00. Het houdadvies van woensdag 19 januari 2022 wordt herhaald. Dit vorige advies heeft geresulteerd in een rendement van -4,42%.
- Bel-Investor
- Forumveteraan
- Berichten: 1320
- Lid geworden op: 29 jan 2022 19:23
- Heeft bedankt: 184 maal
- Is bedankt: 549 maal
Re: ARGENX SE - ARGX - NL0010832176
Ongeveer 1/6 knippen van een koersdoel waarbij het bedrijf ruim een maand geleden de belangrijkste mijlpaal tot nu toe bereikte. De inhoud van de rapporten en motivatie waarom zal wel voor een select aantal grote investeerders te zien zijn.
- Beheerder
- Beheerdersteam
- Berichten: 3015
- Lid geworden op: 04 nov 2021 11:40
- Heeft bedankt: 822 maal
- Is bedankt: 1433 maal
Re: ARGENX SE - ARGX - NL0010832176
+5,2% in de VS, blijkbaar een strong buy van een analist vanwege een succesvolle start van de verkoop van Vygart.
Biotechnology analyst Danielle Brill published on $ARGX "Launch Survey Results: It's Lookin Like a Solid Start for Vyvgart? Reiterate Strong Buy" having surveyed neurologists that treat generalized Myasthenia Gravis to see how the Vyvgart launch is progressing.
- Monniey
- Beginnende poster
- Berichten: 90
- Lid geworden op: 07 dec 2021 18:35
- Heeft bedankt: 95 maal
- Is bedankt: 96 maal
Re: ARGENX SE - ARGX - NL0010832176
Argenx, already deep into its Vyvgart launch, charts course to become immunology 'powerhouse': CEO
by Fraiser Kansteiner | Jan 25, 2022 9:50am
Argenx is charting a course to become an immunology “powerhouse” by the middle of the decade, CEO Tim Van Hauwermeiren said. (Argenx)
With its first FDA-approved drug Vyvgart now rolling out, Argenx is charting a course to become an immunology “powerhouse” by the middle of the decade, CEO Tim Van Hauwermeiren said in a recent interview.
It’s early days for the product’s debut: Vyvgart, also known as efgartigimod, won its green light in generalized myasthenia gravis less than a week before Christmas. But the company's field team mobilized in late December, the drug has now reached its first patients—and its direct-to-consumer advertising has already launched, the CEO said.
Argenx sees its DTC campaign as a way to give a voice to MG patients, Van Hauwermeiren said. The first ad features four real patients talking about why they need a new treatment option—they want to get up and get ready for their day, take care of their animals, go out to dinner with friends and smile in family photos.
It’s not unusual in rare, difficult-to-treat diseases like myasthenia gravis for physicians to think the patient is doing fine, because that patient has adapted to a new normal—despite serious limitations from their disease. Argenx wants to not only spread the word to doctors but to get the news about Vyvgart out to patients to help “equip them to stand up and ask for better [treatment],” the CEO said.
Patients reaching out to neurologists and inquiring about Vyvgart by name would provide a substantial tailwind for the launch, he said.
Argenx is investing heavily in the rollout, aiming to create “economies of scale” to support efgartigimod as it charts four other potential launches by 2024. The company is testing the drug in several other diseases and in a new subcutaneous formulation.
One interesting note about efgartigimod’s subcutaneous formulation? That product will roll out as its own “standalone product,” with its own brand name and its own pricing. That will effectively allow Argenx to “take a second bite at the apple” in myasthenia gravis, Van Hauwermeiren said. Having both delivery formulas “shoulder to shoulder is going to help. It's going to maximize the opportunity in front of us, which we think is very significant,” Van Hauwermeiren said.
Vyvgart carries a wholesale acquisition cost of $5,950 per vial, the CEO said. Given the drug’s weight-based dosing and value-based arrangements with payers, Argenx figures one year of treatment would cost a typical myasthenia gravis patient about $225,000, Van Hauwermeiren said.
By 2025, Argenx hopes efgartigimod will be playing in 15 indications across both the commercial and development spectrum.
Efgartigimod has five phase 3 trials reading out in the next four quarters: First up, a subcutaneous formulation of efgartigimod in myasthenia gravis is due to deliver results in the first quarter of 2021. The quarter after that, argenx is expecting a readout of the first of two registration trials in immune thrombocytopenia, Van Hauwermeiren said. Next comes a pemphigus readout in the fourth quarter, followed by data in chronic inflammatory demyelinating polyradiculoneuropathy in the first three months of 2023.
Argenx isn’t laying out sales forecasts for its so-called “pipeline in a product” just yet. Instead, the first quarter will mainly be about creating demand, Van Hauwermeiren said. The company will do some work toward quantifying that demand in its quarterly earnings call, he added.
Bron https://www.fiercepharma.com/pharma/arg ... rhouse-ceo
by Fraiser Kansteiner | Jan 25, 2022 9:50am
Argenx is charting a course to become an immunology “powerhouse” by the middle of the decade, CEO Tim Van Hauwermeiren said. (Argenx)
With its first FDA-approved drug Vyvgart now rolling out, Argenx is charting a course to become an immunology “powerhouse” by the middle of the decade, CEO Tim Van Hauwermeiren said in a recent interview.
It’s early days for the product’s debut: Vyvgart, also known as efgartigimod, won its green light in generalized myasthenia gravis less than a week before Christmas. But the company's field team mobilized in late December, the drug has now reached its first patients—and its direct-to-consumer advertising has already launched, the CEO said.
Argenx sees its DTC campaign as a way to give a voice to MG patients, Van Hauwermeiren said. The first ad features four real patients talking about why they need a new treatment option—they want to get up and get ready for their day, take care of their animals, go out to dinner with friends and smile in family photos.
It’s not unusual in rare, difficult-to-treat diseases like myasthenia gravis for physicians to think the patient is doing fine, because that patient has adapted to a new normal—despite serious limitations from their disease. Argenx wants to not only spread the word to doctors but to get the news about Vyvgart out to patients to help “equip them to stand up and ask for better [treatment],” the CEO said.
Patients reaching out to neurologists and inquiring about Vyvgart by name would provide a substantial tailwind for the launch, he said.
Argenx is investing heavily in the rollout, aiming to create “economies of scale” to support efgartigimod as it charts four other potential launches by 2024. The company is testing the drug in several other diseases and in a new subcutaneous formulation.
One interesting note about efgartigimod’s subcutaneous formulation? That product will roll out as its own “standalone product,” with its own brand name and its own pricing. That will effectively allow Argenx to “take a second bite at the apple” in myasthenia gravis, Van Hauwermeiren said. Having both delivery formulas “shoulder to shoulder is going to help. It's going to maximize the opportunity in front of us, which we think is very significant,” Van Hauwermeiren said.
Vyvgart carries a wholesale acquisition cost of $5,950 per vial, the CEO said. Given the drug’s weight-based dosing and value-based arrangements with payers, Argenx figures one year of treatment would cost a typical myasthenia gravis patient about $225,000, Van Hauwermeiren said.
By 2025, Argenx hopes efgartigimod will be playing in 15 indications across both the commercial and development spectrum.
Efgartigimod has five phase 3 trials reading out in the next four quarters: First up, a subcutaneous formulation of efgartigimod in myasthenia gravis is due to deliver results in the first quarter of 2021. The quarter after that, argenx is expecting a readout of the first of two registration trials in immune thrombocytopenia, Van Hauwermeiren said. Next comes a pemphigus readout in the fourth quarter, followed by data in chronic inflammatory demyelinating polyradiculoneuropathy in the first three months of 2023.
Argenx isn’t laying out sales forecasts for its so-called “pipeline in a product” just yet. Instead, the first quarter will mainly be about creating demand, Van Hauwermeiren said. The company will do some work toward quantifying that demand in its quarterly earnings call, he added.
Bron https://www.fiercepharma.com/pharma/arg ... rhouse-ceo
- Lama Daila
- Verkenner
- Berichten: 36
- Lid geworden op: 05 jan 2022 21:59
- Heeft bedankt: 15 maal
- Is bedankt: 74 maal
Maak een account aan of log in om deel te nemen aan het forum
Je moet lid zijn om een reactie te kunnen plaatsen
Maak een account aan
Geen lid? Registreer om lid te worden van onze community
Leden kunnen bijlages zien, eigen onderwerpen starten en abonneren op onderwerpen
Het is gratis en duurt maar een minuut
Log in
-
-
Laatste reacties
-
-
- Ga naar laatste bericht Landen in recessie
- Ga naar laatste bericht AIRBUS SE - AIR - NL0000235190
- Ga naar laatste bericht ASML HOLDING - ASML - NL0010273215
- Ga naar laatste bericht CELYAD ONCOLOGY -CYAD - BE0974260896
- Ga naar laatste bericht Philips - PHIA - NL0000009538
- Ga naar laatste bericht Webinars, YouTube kanalen, etc. over beleggen
- Ga naar laatste bericht Fluxys - FLUX - BE0974265945
- Ga naar laatste bericht Oxurion - OXUR - BE0003846632
- Ga naar laatste bericht VINCI SA - DG.PA - Isin FR0000125486
- Ga naar laatste bericht Walgreens Boots Alliance, Inc. - WBA - Isin US9...